The Series B round was led by Kureha Corporation and will accelerate commercial rollout and market expansion.
"We’re delighted to welcome our new corporate and VC investors from Japan and China, as well as having the continued strong support of our existing investors, who together form a world-class group that will help scale CTT quickly to exploit the market opportunity for its technology. CTT has grown rapidly over the last several years, and we’re looking forward to being able to continue executing on our growth plan and sharpening our commercialization focus within the consumer electronics, automotive and industrial markets. The partners we have and the injection of new capital means we can expect to enable our customers to begin rolling out the technology at scale in the near future."
Allectus Capital led the Series A round to support team expansion and platform deployment.
"With the completion of this round, Adarga is focused on consolidating its competitive position in the UK defence and security sector. We are positioning ourselves as the software platform of choice for organisations who cannot deal effectively with the scale and complexity of their enterprise data and are actively seeking an alternative to knowledge intensive human processes. Built by experienced sector specialists, the Company has rapidly progressed a real solution to address the challenges of an ever-growing volume of unstructured data."
The financing round was led by RT Capital Management alongside the Oxford Technology and Innovations EIS Fund.
"Over the last few years Zegami has been developing a cutting edge Visual Data Exploration platform to democratise data analytics, enabling people to make sense of the tsunami of data available today."
The seed round was led by Playfair Capital and will support product development and team expansion.
"Many people living with cancer feel isolated and unsupported, and traditional routes of delivering healthcare struggle to address these issues. It’s also imperative that we gather the necessary data to understand how cancer therapies affect not just survival, but quality of life, so that patients and doctors can weigh up this information to make informed decisions about their care. At Vine, our goal is to put patients back in control."
Conviction Investment Partners led the financing round alongside Triple Point to support global growth.
"This investment comes from continued success and growth for Adepto. To date we have had 100% customer retention, and over the last three years have seen 150% year on year revenue growth."
